MAPT and Alzheimer disease: To assess if the changes in mitophagy biomarkers were influenced by the biomarker profile and severity of the biomarker load, we examined the differences in mitophagy proteins across six ATN profiles based on the positivity (+) or negativity (-) of biomarkers of amyloid beta (A), P-tau181 (T), and T-tau (N) among FTLD and AD patients (A-T-N-, A-T + N-/T-N+, A-T + N+, A + T-N-, A + T + N-, A + T + N+).